Technical Analysis for MDNAF - Medicenna Therapeutics Corp.

Grade Last Price % Change Price Change
grade C 3.82 -4.50% -0.1800
MDNAF closed down 4.5 percent on Friday, July 10, 2020, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical MDNAF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
20 DMA Support Bullish -4.50%
Upper Bollinger Band Touch Strength -6.58%
MACD Bullish Signal Line Cross Bullish -9.05%
Inside Day Range Contraction -9.05%
Upper Bollinger Band Touch Strength -9.05%
Older signals for MDNAF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Medicine Medical Specialties RTT Cancer Clinical Medicine Immunology Treatment Of Cancer Autoimmune Diseases Immunotherapy Solid Tumors Cancer Treatments Tumor Asthma Atopic Dermatitis Fibrosis Immunotherapies Virotherapy Brain Tumor Chimeric Antigen Receptor T Cell Interleukins

Is MDNAF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.32
52 Week Low 0.7218
Average Volume 76,276
200-Day Moving Average 2.3730
50-Day Moving Average 3.8566
20-Day Moving Average 3.9332
10-Day Moving Average 3.9685
Average True Range 0.3403
ADX 21.07
+DI 24.3126
-DI 18.6390
Chandelier Exit (Long, 3 ATRs ) 3.6991
Chandelier Exit (Short, 3 ATRs ) 4.5209
Upper Bollinger Band 4.2743
Lower Bollinger Band 3.5921
Percent B (%b) 0.33
BandWidth 17.3447
MACD Line 0.0244
MACD Signal Line 0.0339
MACD Histogram -0.0095
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.0810
Resistance 3 (R3) 4.1053 4.0427 4.0375
Resistance 2 (R2) 4.0427 3.9762 4.0305 4.0230
Resistance 1 (R1) 3.9313 3.9351 3.9000 3.9070 4.0085
Pivot Point 3.8687 3.8687 3.8530 3.8565 3.8687
Support 1 (S1) 3.7573 3.8022 3.7260 3.7330 3.6315
Support 2 (S2) 3.6947 3.7611 3.6825 3.6170
Support 3 (S3) 3.5833 3.6947 3.6025
Support 4 (S4) 3.5590